NPJ Breast Cancer
Prognostic Significance of TILs in HER2+ Metastatic Breast Cancer
Taurelli Salimbeni B, Giudici F, Pescia C, et al.
This retrospective cohort study was designed to evaluate the prognostic significance of tumor-infiltrating lymphocytes in 110 patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and taxane-based chemotherapy. Overall, the results highlight the potential of tumor-infiltrating lymphocytes as prognostic biomarkers in this population, warranting further investigation.
Previous Article
- • Delphi Consensus for Managing Adverse Events in Patients With Metastatic Triple-Negative Breast Cancer Receiving Sacituzumab Govitecan
- • The Safety and Effectiveness of Palbociclib in Clinical Practice
- • Determinants of HER2-Targeted Therapy Use in Metastatic HR-/HER2+ Breast Cancer
- • Equity of Care Across Metastatic Breast Cancer Treatment
- • Tumor Growth Rate and Survival in Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
- • Patient-Reported Outcomes From DESTINY-Breast04
- • Prognostic Significance of TILs in HER2+ Metastatic Breast Cancer
- • Real-World Consensus on Treating HR+/HER2- Metastatic Breast Cancer
- • Animal Models in Metastatic Breast Cancer Immunotherapy Research
- • PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders
